Skip to content

Psilocybin for anxiety

Studies whose primary subject is both Psilocybin and Anxiety, with an evidence synthesis read across the most-cited and most recent of them.

State of the evidence

Synthesized

Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psilocybin, magic mushrooms, psilocin, psychedelic mushrooms, Anxiety, generalized anxiety disorder, then ranked by relevance.

Across the directly relevant trials, psilocybin-assisted treatment is consistently associated with large reductions in anxiety, particularly in patients with cancer-related or life-threatening illness anxiety, with benefits often sustained for months after one or two doses. A recent meta-analysis reports a large within-group effect and a smaller between-group effect on anxiety symptoms, but high heterogeneity and variable study quality warrant caution. The main caveats are small samples, frequent open-label or crossover designs, and limited blinding, so estimates of specific efficacy remain uncertain.

Evidence by study

Direction is which way each study's own result points, not our rating of the study.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial 2016 RCT 51 Supports High-dose psilocybin produced large decreases in clinician- and self-rated anxiety and depressed mood, with about 80% showing clinically significant improvement sustained at 6 months.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016 RCT 29 Supports Single-dose psilocybin (0.3 mg/kg) plus psychotherapy produced immediate and sustained reductions in anxiety and depression, with roughly 60-80% showing clinically significant reductions at 6.5 months.
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer 2010 double-blind, placebo-controlled study 12 Supports Psilocybin (0.2 mg/kg) was safe and associated with significant reduction in trait anxiety at 1 and 3 months and improved mood.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance 2006 double-blind study 36 Mixed Psilocybin produced acute perceptual changes and labile moods including anxiety, while also increasing mystical-type experience ratings.
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression 2018 clinical trial 20 Supports Oceanic boundlessness and dread of ego dissolution during the psilocybin session predicted improvements in depressive symptoms at 5 weeks.
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder 2006 controlled clinical trial Supports Psilocybin was safely used and associated with acute reductions in core OCD symptoms in several subjects.
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies 2010 pooled analysis 110 Mixed Moderate psilocybin doses were mostly described as pleasurable and non-threatening, but acute anxiety/panic occurred only at the two highest dose conditions in a small proportion of subjects and was managed with support.
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up 2022 randomized waiting-list controlled study 27 Supports Psilocybin-assisted therapy produced large antidepressant effects through 12 months, with 75% response and 58% remission at 12 months.
Emotions and brain function are altered up to one month after a single high dose of psilocybin. 2020 open-label pilot study 12 Supports One month after a single 25 mg/70 kg dose, trait anxiety was reduced and positive affect remained elevated, though negative affect and amygdala response returned to baseline.
Psychedelics as Medicines: An Emerging New Paradigm 2016 theoretical Supports Argues that serotonergic psychedelics may exert therapeutic effects by destabilizing brain network hubs and enabling network resetting, with preliminary evidence of efficacy in anxiety and depression.
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms 2016 questionnaire development and validation Mixed Identified seven factors characterizing challenging psilocybin experiences, including fear and grief, which correlated with difficulty and changes in well-being; factor structure did not differ by prior anxiety or depression.
Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern‐era clinical studies 2020 systematic review 188 Supports Psychedelic-assisted therapy appeared safe and showed promising early efficacy for depression, anxiety, OCD, and substance use disorders, with effects often lasting weeks to months after 1-3 sessions.
Psychedelics and Mental Health: A Population Study 2013 cross-sectional survey 130152 No effect Lifetime psychedelic use was not associated with increased rates of mental health outcomes, including anxiety disorders, and in some cases was associated with lower rates.
Dynamic coupling of whole-brain neuronal and neurotransmitter systems 2020 observational Unclear Describes a framework causally linking 5-HT2A receptor stimulation with psilocybin to brain functional effects, suggesting relevance for depression, anxiety, and addiction.
Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years 2016 systematic review Supports Reviewed clinical trials suggest beneficial effects of ayahuasca, psilocybin, and LSD for treatment-resistant depression and anxiety/depression associated with life-threatening diseases, but all studies had small samples and half were open-label.
Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety 2026 in vitro experimental study Mixed Psilocybe cubensis extract altered gut microbiota composition and metabolism, reducing ammonia and GABA while increasing short-chain fatty acids and Bifidobacterium/Lactobacillus, with a complex immunomodulatory pattern.
A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults. 2026 Phase 1 RCT 56 Supports Low doses of psilocybin (0.5-4.0 mg) produced perceptible pharmacological effects without significant perceptual alterations, cognitive impairment, or increased anxiety.
Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder 2026 review Supports Psilocybin effectively treats common comorbidities like anxiety and treatment-resistant depression, though the review's primary focus is MDMA-assisted therapy for PTSD.
Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior 2026 preclinical animal study Mixed Developmental stress produced sex-specific behavioral and physiological effects, and psilocybin broadly reversed these effects through different behavioral domains in each sex.
Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule? 2026 review Supports Notes growing evidence and multiple FDA Breakthrough Therapy designations for psychedelics, including LSD for generalized anxiety disorder, and discusses policy paths for rescheduling.
Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms 2026 observational study 2841 Supports Past-year psilocybin and alcohol co-use was associated with fewer depressive symptoms, and after removing covariates, psilocybin use was also related to lower anxiety symptoms.
Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 preclinical experimental study Opposes Chronic psilocin microdosing did not affect locomotor activity, depressive-like behavior, sociability, or novelty seeking, and did not increase neurogenesis, though a small anxiogenic effect was observed.
Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes 2026 RCT Supports In a Bayesian reanalysis, women receiving psilocybin showed greater reductions in anxiety than men, while women receiving escitalopram showed greater reductions in anhedonia than men.
Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression. 2026 open-label trial 15 Supports A single 25 mg dose of psilocybin with psychological support was associated with sustained improvements in anxiety (59% reduction at Week 3) through 12 months, though effects were no longer significant after accounting for depressive symptom improvement.
Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis 2026 systematic review and meta-analysis 25 Supports Psilocybin-assisted psychotherapy produced a large within-groups effect (Hedge's g = 0.96) and a small between-groups effect (Hedge's g = 0.48) on anxiety symptoms, with high heterogeneity and variable study quality.

Points of agreement

  • Multiple trials in cancer and life-threatening illness populations report large, sustained reductions in anxiety after psilocybin treatment.
  • Benefits are often observed after one or two doses and can persist for months.
  • Psilocybin is generally reported as safe and well tolerated in controlled research settings, with acute anxiety or panic occurring mainly at higher doses.
  • The quality of the acute experience (e.g., mystical-type or oceanic boundlessness) is reported to predict therapeutic outcomes.
  • A recent meta-analysis supports a large within-group effect on anxiety symptoms, though between-group effects are smaller.

Conflicts

  • Some studies report acute anxiety or panic as a side effect of psilocybin, while others report anxiolytic effects.
  • One preclinical study found a small anxiogenic effect of chronic psilocin microdosing, contrasting with clinical reports of anxiety reduction.
  • The meta-analysis reports high heterogeneity, indicating that effect sizes vary substantially across studies and populations.

Gaps

  • Most trials have small sample sizes and limited blinding, especially in cancer populations.
  • Long-term durability beyond 12 months is not well established.
  • Optimal dosing, number of sessions, and psychotherapy components are not standardized.
  • Few studies focus primarily on anxiety as a primary outcome rather than as a secondary measure in depression trials.
  • Populations studied are narrow (cancer, treatment-resistant depression, veterans), limiting generalizability to other anxiety disorders.
  • Sex-specific effects are only beginning to be examined and require replication.
Browse these studies in the library

Common questions

What does the research agree on about psilocybin for anxiety?
  • Multiple trials in cancer and life-threatening illness populations report large, sustained reductions in anxiety after psilocybin treatment.
  • Benefits are often observed after one or two doses and can persist for months.
  • Psilocybin is generally reported as safe and well tolerated in controlled research settings, with acute anxiety or panic occurring mainly at higher doses.
  • The quality of the acute experience (e.g., mystical-type or oceanic boundlessness) is reported to predict therapeutic outcomes.
  • A recent meta-analysis supports a large within-group effect on anxiety symptoms, though between-group effects are smaller.
Where do studies on psilocybin for anxiety conflict?
  • Some studies report acute anxiety or panic as a side effect of psilocybin, while others report anxiolytic effects.
  • One preclinical study found a small anxiogenic effect of chronic psilocin microdosing, contrasting with clinical reports of anxiety reduction.
  • The meta-analysis reports high heterogeneity, indicating that effect sizes vary substantially across studies and populations.
What is still unknown about psilocybin for anxiety?
  • Most trials have small sample sizes and limited blinding, especially in cancer populations.
  • Long-term durability beyond 12 months is not well established.
  • Optimal dosing, number of sessions, and psychotherapy components are not standardized.
  • Few studies focus primarily on anxiety as a primary outcome rather than as a secondary measure in depression trials.
  • Populations studied are narrow (cancer, treatment-resistant depression, veterans), limiting generalizability to other anxiety disorders.
  • Sex-specific effects are only beginning to be examined and require replication.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Psilocybin for anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Psilocybin for anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

303 articles · 87 from the last two years · 305,867 participants across 109 studies reporting sample size

Common study designs

review 94 systematic review 31 cross-sectional survey 13 randomized controlled trial 14 theoretical or philosophical paper 9

Research volume by year

Compare topics →

301 studies whose primary subject is psilocybin for anxiety since 2006

Studies about psilocybin for anxiety per year, 2006 to 2026, peaking at 51 in 2023 Bar chart: one bar per year, taller where more studies were published that year. 0 30 60 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about psilocybin for anxiety per year, 2006 to 2026, peaking at 51 in 2023
Year Studies
2006 2
2007 0
2008 0
2009 0
2010 2
2011 0
2012 0
2013 1
2014 2
2015 1
2016 9
2017 5
2018 12
2019 10
2020 18
2021 35
2022 44
2023 51
2024 32
2025 44
2026 33

Research

Synthesize the evidence →

Exploring the In Vitro Effect of Psilocybin on the Composition and Metabolic Activity of Gut Microbiota in Individuals with Severe Anxiety

Drugs and Drug Candidates August 12, 2026 M. Salgaço, D. D. Farias, Mariela Zucolo de Souza et al.

Background/Objectives: This study investigated the effects of a single dose of psilocybin-containing Psilocybe cubensis extract on gut microbiota composition, microbial metabolism, and intestinal immune-related responses. Methods: A single dose of P. cubensis extract (35 mg/L) was subjected to colonic fermentation using the SHIME® model inoculated with fecal microbiota from individuals with...

DOI: 10.3390/ddc5030046 (opens in new tab) Full text (opens in new tab)

A randomized, double-blind, placebo-controlled single-ascending-dose study to identify a non-hallucinogenic dose of psilocybin in healthy adults.

medRxiv July 19, 2026 Naama Levy‐Cooperman, Edward M. Sellers, Paul Glue et al. preprint

Psilocybin shows therapeutic promise for several psychiatric disorders, but the acute perceptual and cognitive alterations produced by conventional doses (10-25 mg) require in-clinic supervision, which limits scalability. Whether the therapeutically relevant pharmacology of psilocybin can be separated from its hallucinogenic activity remains unresolved. To address this gap, we conducted a Phase...

DOI: 10.64898/2026.07.16.26358273 (opens in new tab) Psilocybin Anxiety Mescaline Lysergic acid diethylamide +11

Psychedelic Therapies in the Management of Post-Traumatic Stress Disorder

Journal of Education Health and Sport July 16, 2026 Jakub Bajer, Aleksandra Włodarczyk, Hubert Kulawinek et al.

Background. Post-Traumatic Stress Disorder (PTSD) is an important public health challenge typically treated with trauma-focused psychotherapy and Selective Serotonin Reuptake Inhibitors (SSRIs). However, high rates of residual symptoms associated with these standard treatments have led to a renewed interest in psychedelic-assisted therapies. Aim. This review attempts to examine emerging...

DOI: 10.12775/jehs.2026.94.73071 (opens in new tab) Traumatic stress Ketamine Psilocybin Anxiety disorder +5

Sex-specific outcomes of developmental stress and psilocybin intervention on the brain and behavior

Universitätsbibliothek der LMU July 9, 2026 Sowmya Narayan

Stress exposure during periods of neurodevelopment is an established risk factor for the onset of stress-related mental illnesses in adulthood, which have differences in presentation and treatment response depending on an individual’s sex, and are difficult to treat due to a lack of complete biological understanding. A more holistic biological perspective of the adult brain after stress...

DOI: 10.5282/edoc.35588 (opens in new tab) Psilocybin Anxiety Intervention counseling Perspective graphical +9

Policy Considerations for Psychedelics in Research and Medicine – What’s Next on the Schedule?

Journal of Science Policy & Governance July 2, 2026 Matthew A. Boehm, Oriana Mayorga

There is growing interest in psychedelic compounds such as psilocybin, 3,4-metheylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) given emerging research on potential uses as treatments for a variety of health conditions. The United States Food and Drug Administration (FDA) has granted multiple “Breakthrough Therapy” designations to various...

DOI: 10.38126/jspg280103 (opens in new tab) Psilocybin Anxiety Lysergic acid diethylamide Variety cybernetics +6

Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms

Journal of Drug Issues July 1, 2026 Haley M Hummel, Alexia N Obrochta, David C. R. Kerr et al.

Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use...

DOI: 10.1177/00220426261466154 (opens in new tab) Psilocybin Anxiety Cannabis Hallucinogen +8

Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats.

Pharmacology, biochemistry, and behavior June 30, 2026 Lucie Ladislavová, Viera Kútna, Kristýna Mazochová et al.

Psilocin (4-hydroxy-N, N-dimethyltryptamine) is a substituted tryptamine alkaloid and a nonselective serotonergic agonist acting predominantly at 5-HT2A/C receptors, with substantial binding to 5-HT1A and 5-HT2B receptors. Microdosing is the practice of taking a very small, sub-perceptual dose, typically 5% to 10% of a full recreational dose, to improve mood, creativity, and focus without...

DOI: 10.1016/j.pbb.2026.174231 (opens in new tab) Full text (opens in new tab) Anxiety Depression Behavioral testing Hippocampal neurogenesis +3

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes

Research Square June 19, 2026 Aline Frick, Grace Blest‐hopley, Manesh Grin et al. preprint

Abstract Rationale: Major depressive disorder (MDD) shows marked sex differences in prevalence, symptomatology, and treatment response. However, women remain underrepresented in many clinical trials, and sex-specific treatment outcomes are rarely examined. Objectives This study reanalyzed data from a randomized controlled trial comparing psilocybin and escitalopram for MDD to evaluate sex...

DOI: 10.21203/rs.3.rs-9880403/v1 (opens in new tab) Psilocybin Major depressive disorder Anxiety disorder Serotonergic +10

Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression.

Journal of Affective Disorders June 4, 2026 Carlton M Kelly, Mathieu Fradet, Catherine Bostian et al.

Psilocybin has demonstrated promise for improving depressive symptoms in treatment-resistant depression, but its effects on anxiety, quality of life, functioning, and posttraumatic stress symptoms are less well studied. This study reports exploratory findings from an open-label trial in Veterans with TRD. Participants received a single 25-mg dose of psilocybin administered with psychological...

DOI: 10.1016/j.jad.2026.122063 (opens in new tab) Full text (opens in new tab) Anxiety Psilocybin Treatment-resistant depression Posttraumatic stress disorder +1

Effect of psilocybin-assisted psychotherapy on anxiety symptoms: A systematic review and meta-analysis

Journal of Psychedelic Studies May 29, 2026 Alex P. Hood, Gary R Elkins

Abstract Background and Aims Psilocybin-assisted psychotherapy (PAP) is a novel, transdiagnostic treatment in which the 5-HT2A receptor agonist psilocybin is combined with psychotherapy. Studies to date have evaluated PAP's effects on depression, substance use, and end-of-life adjustment. Relatively less attention has been given to its effects on anxiety symptoms, which are highly comorbid with...

DOI: 10.1556/2054.2026.00507 (opens in new tab) Full text (opens in new tab) Anxiety disorder Intervention counseling Systematic review Demographics +8

Clinical trials

All psilocybin for anxiety trials →